O. V. Cutsem

发表

European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small Cell Lung Cancer: III. Metastatic disease

J. Lafitte, P. Houtte, M. Paesmans, 2006 .

A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer

M. Paesmans, J. Sculier, F. Ries, 1994 .

Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer

M. Paesmans, J. Sculier, J. Klastersky, 1994 .

A three-arm phase III randomised trial testing accelerated chemotherapy with GM-CSF or cotrimoxazole in extensive disease smal-cell lung cancer

J. Lafitte, M. Paesmans, J. Sculier, 2001 .

Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).

M. Paesmans, J. Sculier, J. Klastersky, 1996, Lung cancer.

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

M Paesmans, J P Sculier, M. Paesmans, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.

M. Paesmans, J. Sculier, F. Ries, 1994, Lung cancer.

Prognostic factors for patients with small cell lung carcinoma

V. Ninane, M. Paesmans, J. Sculier, 2000, Cancer.

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.

M. Paesmans, J. Sculier, J. Klastersky, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.

M Paesmans, J P Sculier, M. Paesmans, 1997, European journal of cancer.

Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party

J. Lafitte, V. Ninane, M. Paesmans, 2007, British Journal of Cancer.

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.

M. Paesmans, J. Sculier, F. Ries, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

J. Lafitte, V. Ninane, M. Paesmans, 2001, British Journal of Cancer.